

**QIBA Process Committee**  
Wednesday, January 20, 2016 at 3 PM CT  
Call Summary

**Attendees:**

*Kevin O'Donnell, MASC (Chair)*  
Cathy Elsinger, PhD

Nancy Obuchowski, PhD  
Eric Perlman, MD

Nicholas Petrick, PhD

**RSNA Staff:**

Joseph Koudelik  
Susan Weinmann

**Profile Development Stages and Performance Criteria (Mr. O'Donnell)**

- This issue is to be addressed and a recommendation from the Process Committee will be presented at the f2f Steering Committee meeting on January 27, 2016 in Chicago
- Revisions to the Profile stage/version names were suggested to better address issues of feasibility, technical and clinical conformance
- The suggested “practically confirmed” stage will be removed and the technically-confirmed definition will be “softened”
- Many QIBA groups have stalled at the technically-confirmed stage and a definition needs to be confirmed
- What stage of Profile development is beyond the scope of QIBA?:
  - Technically-confirmed and Clinically-confirmed Profile conformance may be beyond QIBA’s scope
  - Need to define point at which a QIBA group’s work is complete
- A broader definition of clinically-confirmed is needed
- Consideration to be given to drafting a performance White Paper
- Need to explore how to parlay Profile requirements into clinical trials
- Mr. O'Donnell to send updated Profile Stages document to RSNA staff for distribution

### **Claim Guidance (Dr. Obuchowski)**

- The latest version of this document, dated December 23, 2015 was presented with the following updates:
  - Additional clarification content was incorporated to the flowchart
  - Real-life references and examples of performance claims were provided where applicable
  - Information from Metrology Group efforts was incorporated
  - The “Selecting a performance metric” flow chart was revised and footnotes were added

**Next Call:** Wednesday, February 10 at 3 PM CT